Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

PhaseBio brings in $40mm in Series C financing led by AstraZeneca

Executive Summary

PhaseBio Pharmaceuticals Inc. (metabolic and cardiopulmonary therapies) raised $40mm through its Series C financing led by AstraZeneca, which was joined by returning shareholders New Enterprise Associates, Hatteras Venture Partners, Johnson & Johnson Development Corp., and Fletcher Spaght Ventures. Funds will help move into Phase IIa both its PE0139 for Type II diabetes and PB1046 for heart failure and cardiomyopathy in Duchenne and Becker muscular dystrophy. AstraZeneca’s Michael Gutch, PhD, takes a seat on PhaseBio's board, and Donald Dwyer joins as an observer.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
      • Controlled Release
  • Biotechnology
    • Large Molecule
    • Synthesis Technologies, Production Processes
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies